Nuwellis Inc is a medical technology company focused on developing innovative solutions for treating fluid overload in patients, specifically targeting those with heart failure and other conditions that lead to the accumulation of excess fluid. The company’s flagship product is designed to enhance the process of fluid removal through a unique approach that combines advanced technology with user-friendly operation, aiming to improve patient outcomes and quality of life. By harnessing cutting-edge medical advancements, Nuwellis strives to offer safer and more effective treatment options for patients who struggle with the complications associated with fluid retention. Read More
The FDA and Nuwellis warn of potential risks linked to AquaFlexFlow UF 500 Plus blood circuits. A recall addresses issues like therapy termination and patient injury risks.
Nuwellis shares are trading higher Monday after the company announced Friday that the first pediatric patient has been treated with the newly launched Quelimmune therapy in a commercial setting.
